Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249127 · ClinicalTrials.gov registry record · Phase 1
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
A Phase 1 study, sponsored by Clarity Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT05249127 is a Phase 1 study that has completed, run by Clarity Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT05249127, a Phase 1 study, has completed, sponsored by Clarity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.
Interventions
- DRUG 64Cu-SAR-bisPSMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05249127
The ClinicalTrials.gov registry entry for NCT05249127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarity Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 64Cu-SAR-bisPSMA is the first listed.
NCT05249127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05249127 about?
NCT05249127 is a clinical study titled "64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)". The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate ca...
What is the current status of trial NCT05249127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-04-11. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05249127?
The interventions under investigation include: 64Cu-SAR-bisPSMA (DRUG).
Who is sponsoring clinical trial NCT05249127?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.